Introduction {#ss1}
============

Asthma is a common medical condition in adults, with a prevalence of 4.5% in Malaysia, based on the National Health and Morbidity Survey 2006. It is an inflammatory disease of the airway which is triggered by external stimuli in genetically-predisposed individuals, leading to mucus secretion, bronchoconstriction and airway narrowing.

The most common symptom is a chronic cough. Misdiagnoses or underdiagnoses cause persistent airway inflammation, airway remodeling, and subsequently, fixed airway obstruction. Therefore, it is important for healthcare professionals to diagnose and manage asthma confidently.

Risk Factors {#ss2}
============

Asthma is a multifactorial disease brought about by various familial and environmental influences, as seen in [Table 1](#t1){ref-type="table"} below:

###### Risk factors for asthma

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Genetic factors
  Environmental factors SmokingAir pollutionPaintPesticides
  Other risk factors/co-morbidities Overweight or obeseGastroesophageal reflux diseaseNasal blockage, rhinorrhea, and allergic rhinitisElevated fractional exhaled nitric oxide and positive skin prick test
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Diagnosis {#ss3}
=========

The diagnosis of asthma is based on a combination of clinical features suggestive of reversible airway obstruction supported by investigations, as shown in [Tables 2](#t2){ref-type="table"} and [3](#t3){ref-type="table"}. A response to treatment may support the diagnosis; however, a lack of response does not exclude asthma.

###### Clinical features of asthma

  ---------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Common symptoms        CoughWheezeChest tightnessShortness of breath
  Symptom variability    Episodic symptomsDiurnal symptomsSymptoms after/during exercise
  Triggers               Common cold (viral infection)Allergens, e.g. dust mites, petsCold weatherIrritants smokehazestrong smells, i.e. perfumes, cleaning solutionsexhaust fumes
  History of atopy       EczemaAllergic rhinitis
  Family history         AsthmaAllergic rhinitisEczema
  Physical examination   EczemaUse of accessory musclesHyperinflationAudible wheezeRonchi on auscultation
  ---------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------

###### Investigations for asthma

  Investigation                                       Description
  --------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Demonstration of airway obstruction*               
  Spirometry                                          A FEV~1~ (forced expiratory volume in 1 second)/FVC (forced vital capacity) ratio of \<70% is a positive test for obstructive airway disease.
  *Demonstration of airway obstruction variability*   
  Bronchodilator reversibility                        An improvement in FEV~1~ of ≥12% **AND** ≥200 ml is a positive bronchodilator reversibility test.
  Other method                                        An increase in FEV~1~ \>12% and \>200 ml \[or peak expiratory flow (PEF) \>20%\] from baseline after four weeks on inhaled corticosteroids (ICS) is a positive test. Patient must not have respiratory infections.
  Peak flow charting                                  Peak flow monitoring over 2 -- 4 weeks.Calculate mean variability. Daily diurnal PEF variability is calculated from twice daily PEFs as \[(day\'s highest --- day\'s lowest)/mean of day\'s highest and lowest\] and averaged over one week.Variability ≥20% or diurnal variation \>15% on \>3 days/week indicates a positive test.

General Principles of Management {#ss4}
================================

The aims of management are to achieve good asthma symptom control and minimise future risk of exacerbations. The partnership between the patients/caregivers and healthcare providers is important in ensuring the success of the management. The patient\'s preferences for treatment, ability to use an inhaler correctly, side effects and cost of medications should be taken into consideration during the treatment process.

Asthma Self-Management {#ss5}
======================

The patient\'s active participation is important in asthma management. All patients should be made aware of the components of asthma self-management, which include: self-monitoring of symptoms and/or PEFa written asthma action plan (WAAP) for optimisation of asthma control through self- adjustment of medicationsa regular medical review by healthcare providers

A home nebuliser should be avoided, as it leads to underestimation of the severity of an acute exacerbation of asthma.

Stable Asthma {#ss6}
=============

Stable asthma is defined as the absence of symptoms, no limitations on activities and not requiring any relievers in the last four weeks.

a.. Assessment of asthma control {#ss7}
--------------------------------

Asthma control can be assessed by using Asthma Control Test (ACT) scores or asking recommended questions, as shown in [Table 4](#t4){ref-type="fig"} below.
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b.. Assessment of the severity of future risks {#ss8}
----------------------------------------------

Assessment of the risk factors for a poor asthma outcome is important in treatment adjustments and prediction of exacerbation. Refer to [Table 5](#t5){ref-type="table"} for more details.

###### Investigations for asthma

  --------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Risk factors for poor asthma outcome**                                                                                    
  Assess risk factors at diagnosis and periodically (1 -- 2 years)Measure FEV^1^ at the start of treatment and periodically   
  Independent risk factors                                                                                                    Having one or more of these risk factors increases the risk of exacerbations, even if symptoms are well-controlled: Uncontrolled asthma symptomsICS not prescribed, poor ICS adherence, incorrect inhaler techniqueHigh short-acting β~2~-agonists (SABA) useLow FEV~1~, especially if \<60% predictedMajor psychological or socioeconomic problemsExposures: smoking; allergen exposure, if sensitisedCo-morbidities: obesity, rhinosinusitis, confirmed food allergySputum or blood eosinophilia, elevated fractional exhaled nitric oxide in allergic adultsPregnancyEver being intubated or in intensive care for asthmaHaving ≥1 severe exacerbations in the last 12 months
  Risk factors for fixed airflow limitation                                                                                   Lack of ICS treatmentExposure to tobacco smokeNoxious chemical or occupational exposuresLow FEV~1~Chronic mucus hypersecretionSputum or blood eosinophilia
  Risk factors for medication side effect                                                                                     Systemic: frequent oral corticosteroids (OCS); long-term, high-dose ICS; taking P450 inhibitors, e.g. itraconazole, ketoconazole, etc.Local: high-dose or potent ICS, poor inhaler technique
  --------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

c.. Treatment {#ss9}
-------------

The goal of asthma treatment is to achieve and maintain symptom control. This is done using a stepwise approach, as shown in [Figure 1](#f1){ref-type="fig"}. Any of the following issues should be addressed before considering treatment adjustment: inhaler techniqueadherence to medicationsmodifiable risk factorspresence of co-morbidities
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-   **Reliever** Inhaled SABA are the reliever of choice in stable asthma. Oral SABA should be avoided in asthma due to their side effects.A low dose of budesonide/formoterol or beclometasone/formoterol may be used as a single inhalant for maintenance and reliever therapy in moderate to severe asthma.Inhaled long-acting β~2~-agonists without ICS should not be used in reliever monotherapy in stable asthma.

-   **Controller (in addition to as-needed reliever inhaler)** ICS are the preferred controller therapy in asthma.Initiation of ICS should not be delayed in symptomatic asthma.Low-dose ICS should be considered in steroid-naïve, symptomatic asthma.Long-acting β~2~-agonists should not be used as controller monotherapy without ICS in asthma.Leukotriene receptor antagonists as add-on can be beneficial in patients with concomitant seasonal allergic rhinitis and asthma.The soft-mist inhaler tiotropium may be used as add-on therapy in patients with asthma that is not well-controlled with medium- or high-dose ICS.Patients with difficult-to-control asthma should be referred to a respiratory physician.

Non-Pharmacological Treatment {#ss10}
=============================

Non-pharmacological treatments may improve symptom control and/or reduce future risk of asthma exacerbation. This includes smoking cessation, vaccination and weight loss management.

Acute Exacerbation of Asthma {#ss11}
============================

Acute exacerbation of asthma is defined as a progressive or sudden onset of worsening symptoms. Status asthmaticus is a life-threatening and medical emergency situation.

a.. Assessment of severity and management {#ss12}
-----------------------------------------

Rapid clinical assessment of severity (refer to [Table 6](#t6){ref-type="table"}) should be performed in all acute exacerbation of asthma. Treatment should be initiated immediately based on the severity of the asthma (refer to [Algorithm 1](#alg1){ref-type="fig"}).

###### Level of severity of acute exacerbation of asthma

  Severity                                                                         Clinical features                                                     Clinical parameters
  -------------------------------------------------------------------------------- --------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------
  Mild to moderate                                                                 Speaks in phrasesSits upNot agitated                                  Respiratory Rate (RR): 20 -- 30/minPulse rate (PR): 100 -- 120/minO~2~ saturation: 90 -- 95%PEF: \>50% predicted or best
  Severe                                                                           Speaks in wordsSits forwardAgitatedAccessory muscles used             RR: \>30/minPR: \>120/minO~2~: Saturation \<90%PEF: \<50% predicted or best
  Life-threatening                                                                 Severe asthma with **ANY OF THE FOLLOWING:**                          
  DrowsyConfusedExhaustionCyanosisHypotensionSilent chestPoor respiratory effort   PEF: \<33%PaO~2~: \<60 mmHgNormal (30 -- 45 mmHg) or raised PaCO~2~   

In acute exacerbation of asthma, inhaled β~2~-agonists are the first-line treatment. In mild to moderate exacerbations, a pressurised metered dose inhaler with a spacer is the preferred method of delivery.In severe and life-threatening exacerbations, continuous delivery of nebulised oxygen-driven β~2~-agonists should be used.

Systemic corticosteroids should be given to all patients with acute exacerbation of asthma. They should be continued for 5 to 7 days. Asthma patients prescribed OCS should continue their regular ICS.

b.. Criteria for admission/discharge {#ss13}
------------------------------------

All patients with severe, life-threatening asthma and those with PEF\<75% personal best or predicted one hour after initial treatment should be admitted. The following factors may be considered for admission: persistent symptomspregnancyprevious near-fatal asthma attackdeteriorating PEFliving alone/socially isolatedpersisting or worsening hypoxiapsychological problemsexhaustionphysical disability or learning difficultiesdrowsiness, confusion or altered conscious stateasthma attack despite recent adequate steroid treatmentrespiratory arrest

Patients with resolution of symptoms and PEF \>75% personal best or predicted one hour after initial treatment may be discharged home with a WAAP
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Referral {#ss14}
========

A referral to a specialist with experience in asthma should be made for asthma patients with the following conditions: diagnosis of asthma is not clearsuspected occupational asthmapoor response to asthma treatmentpersistent use of high-dose ICS without being able to taper offsymptoms remain uncontrolled with persistent use of high-dose ICSpersistent symptoms despite continuous use of moderate- to high-dose ICS combined with LABAsevere/life-threatening asthma exacerbationsasthma in pregnancyasthma with multiple co-morbidities

Details of the evidence supporting the above statements can be found in the Clinical Practice Guidelines on the Management of Asthma in Adults 2017, available on the following websites: Ministry of Health Malaysia: <http://www.moh.gov.my> and Academy of Medicine: <http://www.acadmed.org.my>. Corresponding organisation: CPG Secretariat, Health Technology Assessment Section, Medical Development Division, Ministry of Health Malaysia, contactable at <htamalaysia@moh.gov.my>
